We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. --- We were formed in August 2013 under the laws of the state of Delaware under the name AdCyte LLC. In July 2014, we changed our name to ViraCyte LLC. In September 2018, we converted from a Delaware limited liability company to a Delaware corporation and changed our name to ViraCyte, Inc. In May 2019, we changed our name to AlloVir, Inc. Our principal executive offices are located at 139 Main Street, Suite 500, Cambridge, MA 02142, and our phone number is 617-433-2605. We have three wholly-owned subsidiaries, AlloVir International Designated Activity Company, AlloVir Securities Corporation and AlloVir Italia S.R.L., each of which was formed in 2019. Our website address is www.AlloVir.com.

Allovir, Inc.

We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.

Should you buy, sell, or hold Allovir, Inc. (ALVR) ?

Allovir, Inc. (ALVR) : Buy or Sell